2021 Revenues ($USD) : $11,787,000,000
2021 R&D spend : $1,300,000,000
2021 Number of Employees : not available
Fiscal Year End : 12/31/2020
Key People : Miles White, executive chair; Robert Ford, president and CEO; Hubert Allen, EVP, general counsel and secretary; John Capek, EVP, ventures; Lisa Earnhardt, EVP, medical devices; Robert Funck Jr., EVP, finance and CFO; John Ginascol, EVP, core diagnostics; Andrew Lane, EVP, established pharmaceuticals; Mary Moreland, EVP, human resources; Daniel Salvadori, EVP, nutritional products; Andrea Wainer, EVP, rapid and molecular diagnostics; Greg Ahlberg, SVP, core laboratory diagnostics, commercial operations; Christopher Calamari, SVP, U.S. nutrition; Michael Dale, SVP, structural heart; Scott House, SVP, quality assurance regulatory and engineering services; Sammy Karam, SVP, emerging markets established pharmaceuticals; Joseph Manning, SVP, international nutrition; Louis Morrone, SVP, rapid diagnostics; Michael Pederson, SVP, electrophysiology and heart failure; Julie Tyler, SVP, vascular; Jared Watkin, SVP, diabetes care; Alejandro Wellisch, SVP, established pharmaceuticals, Latin America; Randel Woodgrift, SVP, cardiac rhythm management.

About the company: Abbott Park, Illinois-based Abbott was founded in 1894 and was originally incorporated as the Abbott Alkaloidal Company. It made "alkaloidal" medicine granules and later produced its first synthetic medicine, the antiseptic Chlorazene. By 1972, Abbott was beginning its modern diagnostics business with its ABA-100 blood chemistry analyzer that detected serum hepatitis. Abbott was also an early player in continuous glucose monitors with the launch of its FreeStyle Libre in 2014. The device eliminated the need for routine fingersticks when testing for glucose in people living with diabetes. The company made a big leap into the medical device space with its largest acquisition to date — its $25 billion purchase of St. Jude Medical in 2017. The purchase added innovations in cardiovascular and neuromodulation devices to Abbott's portfolio of technology. The company has continued to innovate on its investments and entered the TAVR market in September this year, competing against Edwards Lifesciences and Medtronic with its FDA-approved Portico with FlexNav. Some of the cardiac conditions Abbott designs its devices to treat include cardiac arrhythmias, coronary artery disease, heart failure and heart valve disease. The company is also making specialized devices for spinal cord stimulation to treat chronic pain. Abbott has been an integral part of efforts against the COVID-19 pandemic, as it provided numerous diagnostic tests for the virus. It was one of the first companies to launch a commercial at-home rapid COVID-19 test kit, the BinaxNow. –DK